Screening Protocol to Evaluate Acid Alpha-Glucosidase (GAA) Activity and GAA Gene Mutations in Patients With Late Onset Pompe Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

60 participants

Study Classification

OBSERVATIONAL

Study Start Date

2005-05-31

Study Completion Date

2005-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Pompe disease (also known as glycogen storage disease type II) is caused by a deficiency of a critical enzyme in the body called acid alpha-glucosidase (GAA). Normally, GAA is used by the body's cells to break down glycogen (a stored form of sugar) within specialized structures called lysosomes. In patients with Pompe disease, an excessive amount of glycogen accumulates and is stored in various tissues, especially heart and skeletal muscle, which prevents their normal function. The primary objective of this study is to identify potential candidates for future clinical studies in Pompe disease.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Prospective, Observational Study in Patients With Late-Onset Pompe Disease

NCT00077662

Glycogen Storage Disease Type II

COMPLETED

A Placebo-Controlled Study of Safety and Effectiveness of Myozyme (Alglucosidase Alfa) in Patients With Late-Onset Pompe Disease

NCT00158600

Pompe Disease (Late-onset) Glycogen Storage Disease Type II (GSD-II) Acid Maltase Deficiency Disease +1 more

COMPLETED PHASE3

A Study of rhGAA in Patients With Late-Onset Pompe Disease

NCT00250939

Pompe Disease (Late-onset) Glycogen Storage Disease Type II (GSD-II) Acid Maltase Deficiency Disease +1 more

COMPLETED PHASE2

Late-Onset Treatment Study Extension Protocol

NCT00455195

Pompe Disease (Late-Onset) Glycogen Storage Disease Type II (GSD-II) Glycogenesis Type II +1 more

COMPLETED PHASE4

Expanded Access Use of Myozyme (Alglucosidase Alfa) in Patients With Late-onset Pompe Disease

NCT00074932

Glycogen Storage Disease Type II Glycogenosis 2

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pompe Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with late onset Pompe Disease

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Must provide written informed consent prior to any study-related procedures being performed
* Clinical presentation consistent with late-onset Pompe disease, or a current clinical diagnosis of late-onset Pompe disease
* Must be greater than or equal to 8 years of age
* Must be able to ambulate (use of assistive devices, such as a walker, cane or crutches, is permitted)

Exclusion Criteria

* Requires the use of invasive ventilatory support
* Requires the use of noninvasive ventilatory support while awake and in an upright position
* Use of any investigational product within 30 days prior to study enrollment
* Unwillingness to comply with protocol requirements
* Has clinically significant organic disease, unstable medical condition, serious or intercurrent illness
* Is pregnant or lactating
* Has participated in the Prospective Observational Study in Patients with Late-Onset Pompe Disease (AGLU02303, "LOPOS")

Minimum Eligible Age

8 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No